---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000004"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:26:28.000425+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences reports preliminary Q4 2021 INGREZZA sales ~$301M, FY ~$1.1B

## Summary
- Q4 INGREZZA net sales ~$301M ($296M inventory-adjusted), up 25% YoY; prescriptions up 32% YoY.
- Full-year 2021 INGREZZA net sales ~$1.1B.
- Full-year 2022 INGREZZA sales guidance to be provided on Feb 11, 2022 earnings call.
- Pipeline: sNDA for valbenazine in Huntington chorea in 2H 2022; Phase 2 data for NBI-827104 mid-2022.
- Company now has 13 mid-to-late-stage clinical programs with data readouts over the next two years.

## SEC filing metadata
- accession: 0000914475-22-000004
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000004/0000914475-22-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000004/nbix-20220106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000004
- JSON: https://secwatch.observer/filing/0000914475-22-000004.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.